Literature DB >> 24085769

Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes.

Justin D Walter1, Rachel A Werther, Caileen M Brison, Rebecca K Cragerud, John F Healey, Shannon L Meeks, Pete Lollar, P Clint Spiegel.   

Abstract

The factor VIII C2 domain is a highly immunogenic domain, whereby inhibitory antibodies develop following factor VIII replacement therapy for congenital hemophilia A patients. Inhibitory antibodies also arise spontaneously in cases of acquired hemophilia A. The structural basis for molecular recognition by 2 classes of anti-C2 inhibitory antibodies that bind to factor VIII simultaneously was investigated by x-ray crystallography. The C2 domain/3E6 FAB/G99 FAB ternary complex illustrates that each antibody recognizes epitopes on opposing faces of the factor VIII C2 domain. The 3E6 epitope forms direct contacts to the C2 domain at 2 loops consisting of Glu2181-Ala2188 and Thr2202-Arg2215, whereas the G99 epitope centers on Lys2227 and also makes direct contacts with loops Gln2222-Trp2229, Leu2261-Ser2263, His2269-Val2282, and Arg2307-Gln2311. Each binding interface is highly electrostatic, with positive charge present on both C2 epitopes and complementary negative charge on each antibody. A new model of membrane association is also presented, where the 3E6 epitope faces the negatively charged membrane surface and Arg2320 is poised at the center of the binding interface. These results illustrate the potential complexities of the polyclonal anti-factor VIII immune response and further define the "classical" and "nonclassical" types of antibody inhibitors against the factor VIII C2 domain.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24085769      PMCID: PMC3868927          DOI: 10.1182/blood-2013-08-519124

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  60 in total

1.  Electrostatics of nanosystems: application to microtubules and the ribosome.

Authors:  N A Baker; D Sept; S Joseph; M J Holst; J A McCammon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Interactions between residues 2228-2240 within factor VIIIa C2 domain and factor IXa Gla domain contribute to propagation of clot formation.

Authors:  T Soeda; K Nogami; K Ogiwara; M Shima
Journal:  Thromb Haemost       Date:  2011-09-22       Impact factor: 5.249

3.  Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII.

Authors:  P C Spiegel; M Jacquemin; J M Saint-Remy; B L Stoddard; K P Pratt
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

4.  Immunochemical characterization of factor VIII inhibitors.

Authors:  L W Hoyer; M S Gawryl; B de la Fuente
Journal:  Prog Clin Biol Res       Date:  1984

Review 5.  Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.

Authors:  I Scharrer; G L Bray; O Neutzling
Journal:  Haemophilia       Date:  1999-05       Impact factor: 4.287

6.  Role of factor VIII C2 domain in factor VIII binding to factor Xa.

Authors:  K Nogami; M Shima; K Hosokawa; T Suzuki; T Koide; E L Saenko; D Scandella; M Shibata; S Kamisue; I Tanaka; A Yoshioka
Journal:  J Biol Chem       Date:  1999-10-22       Impact factor: 5.157

7.  A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.

Authors:  M Shima; D Scandella; A Yoshioka; H Nakai; I Tanaka; S Kamisue; S Terada; H Fukui
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

9.  The tertiary structure and domain organization of coagulation factor VIII.

Authors:  Betty W Shen; Paul Clint Spiegel; Chong-Hwan Chang; Jae-Wook Huh; Jung-Sik Lee; Jeanman Kim; Young-Ho Kim; Barry L Stoddard
Journal:  Blood       Date:  2007-10-26       Impact factor: 22.113

10.  A role for the C2 domain of factor VIII in binding to von Willebrand factor.

Authors:  E L Saenko; M Shima; K J Rajalakshmi; D Scandella
Journal:  J Biol Chem       Date:  1994-04-15       Impact factor: 5.157

View more
  13 in total

1.  Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.

Authors:  P M Zakas; K Vanijcharoenkarn; R C Markovitz; S L Meeks; C B Doering
Journal:  J Thromb Haemost       Date:  2014-11-11       Impact factor: 5.824

2.  High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.

Authors:  Phuong-Cac T Nguyen; Kenneth B Lewis; Ruth A Ettinger; Jason T Schuman; Jasper C Lin; John F Healey; Shannon L Meeks; Pete Lollar; Kathleen P Pratt
Journal:  Blood       Date:  2014-03-03       Impact factor: 22.113

Review 3.  Engineering less immunogenic and antigenic FVIII proteins.

Authors:  Kathleen P Pratt
Journal:  Cell Immunol       Date:  2015-11-02       Impact factor: 4.868

4.  High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.

Authors:  Glaivy Batsuli; Wei Deng; John F Healey; Ernest T Parker; W Hunter Baldwin; Courtney Cox; Brenda Nguyen; Joerg Kahle; Christoph Königs; Renhao Li; Pete Lollar; Shannon L Meeks
Journal:  Blood       Date:  2016-07-05       Impact factor: 22.113

5.  The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain.

Authors:  Ian W Smith; Anne E d'Aquino; Christopher W Coyle; Andrew Fedanov; Ernest T Parker; Gabriela Denning; Harold Trent Spencer; Pete Lollar; Christopher B Doering; Paul Clint Spiegel
Journal:  J Thromb Haemost       Date:  2019-09-08       Impact factor: 5.824

6.  Structure of blood coagulation factor VIII in complex with an anti-C1 domain pathogenic antibody inhibitor.

Authors:  Joseph S Gish; Lexi Jarvis; Kenneth C Childers; Shaun C Peters; Connor S Garrels; Ian W Smith; H Trent Spencer; Christopher B Doering; Pete Lollar; P Clint Spiegel
Journal:  Blood       Date:  2021-05-27       Impact factor: 25.476

7.  Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody.

Authors:  Jasper C Lin; Ruth A Ettinger; Jason T Schuman; Ai-Hong Zhang; Muhammad Wamiq-Adhami; Phuong-Cac T Nguyen; Shelley M Nakaya-Fletcher; Komal Puranik; Arthur R Thompson; Kathleen P Pratt
Journal:  PLoS One       Date:  2015-01-23       Impact factor: 3.240

Review 8.  Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress.

Authors:  Sriram Krishnaswamy; Walter Ageno; Yaseen Arabi; Tiziano Barbui; Suzanne Cannegieter; Marc Carrier; Audrey C Cleuren; Peter Collins; Laurence Panicot-Dubois; Jane E Freedman; Kathleen Freson; Philip Hogg; Andra H James; Colin A Kretz; Michelle Lavin; Frank W G Leebeek; Weikai Li; Coen Maas; Kellie Machlus; Michael Makris; Ida Martinelli; Leonid Medved; Marguerite Neerman-Arbez; James S O'Donnell; Jamie O'Sullivan; Madhvi Rajpurkar; Verena Schroeder; Paul Clinton Spiegel; Simon J Stanworth; Laura Green; Anetta Undas
Journal:  Res Pract Thromb Haemost       Date:  2021-07-16

9.  Structure of the Human Factor VIII C2 Domain in Complex with the 3E6 Inhibitory Antibody.

Authors:  Michelle E Wuerth; Rebecca K Cragerud; P Clint Spiegel
Journal:  Sci Rep       Date:  2015-11-24       Impact factor: 4.379

10.  Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor.

Authors:  Estelle K Ronayne; Shaun C Peters; Joseph S Gish; Celena Wilson; H Trent Spencer; Christopher B Doering; Pete Lollar; P Clint Spiegel; Kenneth C Childers
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.